학술논문
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
Document Type
Article
Author
Hoeper, Marius M; Al-Hiti, Hikmet; Benza, Raymond L; Chang, Sung-A; Corris, Paul A; Gibbs, J Simon R; Grünig, Ekkehard; Jansa, Pavel; Klinger, James R; Langleben, David; McLaughlin, Vallerie V; Meyer, Gisela M B; Ota-Arakaki, Jaquelina; Peacock, Andrew J; Pulido, Tomás; Rosenkranz, Stephan; Vizza, Carmine Dario; Vonk-Noordegraaf, Anton; White, R James; Chang, Mikyung; Kleinjung, Frank; Meier, Christian; Paraschin, Karen; Ghofrani, Hossein Ardeschir; Simonneau, Gérald; Olschewski, H; Delcroix, M; Andrade-Lima, M; de Amorim Corrêac, R; Figueiredo Campos, F; Ota Arakaki, J; Meyer, G; De Souza, R; Langleben, D; Al-Hiti, H; Jansa, P; Mellemkjær, S; Bauer, F; Montani, D; Simonneau, G; Drömann, D; Ghofrani, H-A; Grünig, E; Halank, M; Held, M; Hoeper, MM; Klose, H; Kneidinger, N; Leuchte, H; Opitz, C; Rosenkranz, S; Wilkens, H; Wirtz, H; Karvounis, H; Pitsiou, G; Orfanos, S; D'Alto, M; Ghio, S; Vizza, CD; Vitulo, P; Nakayama, T; Maki, H; Tatebe, S; de los Rios Ibarra, M; Pulido, T; Van Dijk, A; Vonk-Noordegraaf, A; Roleder, T; Castro, G; Loureiro, MJ; Robalo-Martins, S; Barberá, JA; Lázaro, M; Perez-Penate, GM; Román, A; Cheng, C-C; Hsu, C-H; Hsu, H-H; Atahan, E; Mogulkoc Bishop, N; Okumus, NG; Onen, Z; Chang, H-J; Chang, S-A; Lee, J-S; Kim, H-K; Coghlan, JG; Corris, PA; Church, AC; Condliffe, R; Gibbs, JSR; Peacock, AJ; Wort, S; Allen, R; Allen, S; Awdish, R; Benza, RL; DeSouza, S; Feldman, J; Johri, S; Klinger, JR; Layish, D; McConnell, J; McLaughlin, VV; Migliore, C; Rahaghi, F; Rischard, F; Robbins, I; Satterwhite, L; Shah, T; Sulica, R; White, RJ
Source
The Lancet Respiratory Medicine; 20210101, Issue: Preprints
Subject
Language
ISSN
22132600; 22132619
Abstract
Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of riociguat and PDE5i in these patients are needed. The aim of this trial was to assess the effects of switching to riociguat from PDE5i therapy versus continued PDE5i therapy in patients with PAH at intermediate risk of 1-year mortality.